1,647 Shares in Becton, Dickinson and Company $BDX Purchased by Lecap Asset Management Ltd.

Key Points

• Lecap Asset Management Ltd. acquired 1,647 shares of Becton, Dickinson and Company worth approximately $284,000 in the second quarter, indicating growing interest in the medical supplier's stock.
• The company reported $3.68 earnings per share for its latest quarter, exceeding expectations and reflecting a 10.4% increase in revenue compared to the previous year.
• Becton, Dickinson and Company recently declared a quarterly dividend of $1.04 per share, resulting in an annualized dividend yield of 2.1%.

Lecap Asset Management Ltd. acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,647 shares of the medical instruments supplier's stock, valued at approximately $284,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Northcape Wealth Management LLC increased its position in Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after purchasing an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after buying an additional 53 shares during the last quarter. Brady Family Wealth LLC boosted its stake in Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after buying an additional 53 shares during the last quarter. Diversified Trust Co boosted its stake in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after buying an additional 53 shares during the last quarter. Finally, Horizon Bancorp Inc. IN boosted its stake in Becton, Dickinson and Company by 10.9% in the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier's stock worth $130,000 after buying an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $193.67 on Friday. The firm has a market capitalization of $55.51 billion, a P/E ratio of 34.83, a P/E/G ratio of 1.50 and a beta of 0.25. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The business's 50-day simple moving average is $189.03 and its 200-day simple moving average is $187.68.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company's payout ratio is 74.82%.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock worth $562,036 over the last three months. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BDX. Weiss Ratings reissued a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Saturday, September 27th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Morgan Stanley raised their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Argus lifted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of "Hold" and an average target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.